The North America Hemoglobinopathies Market would witness market growth of 5.1% CAGR during the forecast period (2022-2028).
Tetramer hemoglobin consists of two alpha globin and two non-alpha globin chains, and Heme works together to deliver oxygen into the blood. ΑA2 and βA2 represent normal adult hemoglobin (HbA). Gene abnormalities are the cause of variant hemoglobin which affects the alpha globin genes (HBA1 or HBA2) or beta-globin (HBB) structural gene (exons). More than thousands of different variants of hemoglobin related to changes in globin chains have been found.
Qualitative abnormalities like amino acid substitution cause hemoglobinopathies. Thalassemia corresponds to quantitative alterations like amino acid insertions, mutations, or deletions in the adjacent sequences (introns), which decrease the globin chain synthesis. Alterations in the Alpha globin genes cause Alpha thalassemia. The four alleles of HBA1 and HBA2 control the synthesis of alpha-globin.
The number of alpha gene deletions depends upon the degree of the disease in the deletion type alpha thalassemia. Deletion of one alpha globin (also known as the silent carrier) gene is ordinary. In contrast, two alpha globin gene deletions (alpha thalassemia trait) and three alpha globin gene deletions (HbH disease) will have different hematological and clinical features. A four alpha-globin gene (Hb Bart’s Hydrops fetalis) deletion is severe and lethal for patients.
Numerous newborn screening programs are being conducted in the United States with the target of finding out the rate of complications and the actual usage of early medications like pneumococcal vaccination and penicillin prophylaxis to find out the usage and effectiveness of the prevention programs among the large population of infants with hemoglobinopathy. Every newborn in Illinois, New York, and California are scanned for hemoglobinopathies. Screening programs were implemented in California, New York, and Illinois between the years 1975 and 1990.
The US market dominated the North America Hemoglobinopathies Market by Country in 2021; thereby, achieving a market value of $1.6 Million by 2028. The Canada market is experiencing a CAGR of 7.5% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 6.5% during (2022 - 2028).
Based on Type, the market is segmented into Thalassemia, Sickle Cell Disease and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacy, Hospital Pharmacy and Online Providers. Based on Therapy, the market is segmented into Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Hemoglobinopathies Market is Estimated to reach $6 Billion by 2028, at a CAGR of 5.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Sanofi S.A., Danaher Corporation, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Merck & Co., Inc., Bristol Myers Squibb Company, Alnylam Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., Biogen, Inc. and Canthera Discovery Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Thalassemia
- Sickle Cell Disease
- Others
By Distribution Channel
- Drug Stores & Retail Pharmacy
- Hospital Pharmacy
- Online Providers
By Therapy
- Monoclonal Antibody Medication
- Hydroxyurea
- ACE Inhibitors
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Sanofi S.A.
- Danaher Corporation
- Pfizer, Inc. (Global Blood Therapeutics, Inc.)
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Alnylam Pharmaceuticals, Inc.
- Emmaus Life Sciences, Inc.
- Biogen, Inc.
- Canthera Discovery Ltd.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Hemoglobinopathies Market, by Type
1.4.2 North America Hemoglobinopathies Market, by Distribution Channel
1.4.3 North America Hemoglobinopathies Market, by Therapy
1.4.4 North America Hemoglobinopathies Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and Scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Hemoglobinopathies Market by Type
3.1 North America Thalassemia Market by Country
3.2 North America Sickle Cell Disease Market by Country
3.3 North America Others Market by Country
Chapter 4. North America Hemoglobinopathies Market by Distribution Channel
4.1 North America Drug Stores & Retail Pharmacy Market by Country
4.2 North America Hospital Pharmacy Market by Country
4.3 North America Online Providers Market by Country
Chapter 5. North America Hemoglobinopathies Market by Therapy
5.1 North America Monoclonal Antibody Medication Market by Country
5.2 North America Hydroxyurea Market by Country
5.3 North America ACE Inhibitors Market by Country
5.4 North America Others Market by Country
Chapter 6. North America Hemoglobinopathies Market by Country
6.1 US Hemoglobinopathies Market
6.1.1 US Hemoglobinopathies Market by Type
6.1.2 US Hemoglobinopathies Market by Distribution Channel
6.1.3 US Hemoglobinopathies Market by Therapy
6.2 Canada Hemoglobinopathies Market
6.2.1 Canada Hemoglobinopathies Market by Type
6.2.2 Canada Hemoglobinopathies Market by Distribution Channel
6.2.3 Canada Hemoglobinopathies Market by Therapy
6.3 Mexico Hemoglobinopathies Market
6.3.1 Mexico Hemoglobinopathies Market by Type
6.3.2 Mexico Hemoglobinopathies Market by Distribution Channel
6.3.3 Mexico Hemoglobinopathies Market by Therapy
6.4 Rest of North America Hemoglobinopathies Market
6.4.1 Rest of North America Hemoglobinopathies Market by Type
6.4.2 Rest of North America Hemoglobinopathies Market by Distribution Channel
6.4.3 Rest of North America Hemoglobinopathies Market by Therapy
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Sanofi S.A.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Trials and Approvals:
7.3 Danaher Corporation
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 Pfizer, Inc. (Global Blood Therapeutics, Inc.)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional & Segmental Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 Merck & Co., Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expenses
7.6 Bristol Myers Squibb Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Alnylam Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expense
7.8 Emmaus Life Sciences, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.9 Biogen, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.10. Canthera Discovery Ltd.
7.10.1 Company Overview
TABLE 1 North America Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 2 North America Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 3 North America Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 4 North America Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 5 North America Thalassemia Market by Country, 2018 - 2021, USD Million
TABLE 6 North America Thalassemia Market by Country, 2022 - 2028, USD Million
TABLE 7 North America Sickle Cell Disease Market by Country, 2018 - 2021, USD Million
TABLE 8 North America Sickle Cell Disease Market by Country, 2022 - 2028, USD Million
TABLE 9 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 10 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 11 North America Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 12 North America Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 13 North America Drug Stores & Retail Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 14 North America Drug Stores & Retail Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 15 North America Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 16 North America Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 17 North America Online Providers Market by Country, 2018 - 2021, USD Million
TABLE 18 North America Online Providers Market by Country, 2022 - 2028, USD Million
TABLE 19 North America Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 20 North America Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 21 North America Monoclonal Antibody Medication Market by Country, 2018 - 2021, USD Million
TABLE 22 North America Monoclonal Antibody Medication Market by Country, 2022 - 2028, USD Million
TABLE 23 North America Hydroxyurea Market by Country, 2018 - 2021, USD Million
TABLE 24 North America Hydroxyurea Market by Country, 2022 - 2028, USD Million
TABLE 25 North America ACE Inhibitors Market by Country, 2018 - 2021, USD Million
TABLE 26 North America ACE Inhibitors Market by Country, 2022 - 2028, USD Million
TABLE 27 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 28 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 29 North America Hemoglobinopathies Market by Country, 2018 - 2021, USD Million
TABLE 30 North America Hemoglobinopathies Market by Country, 2022 - 2028, USD Million
TABLE 31 US Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 32 US Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 33 US Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 34 US Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 35 US Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 36 US Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 37 US Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 38 US Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 39 Canada Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 40 Canada Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 41 Canada Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 42 Canada Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 43 Canada Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 44 Canada Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 45 Canada Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 46 Canada Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 47 Mexico Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 48 Mexico Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 49 Mexico Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 50 Mexico Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 51 Mexico Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 52 Mexico Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 53 Mexico Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 54 Mexico Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 55 Rest of North America Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 56 Rest of North America Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 57 Rest of North America Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 58 Rest of North America Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 59 Rest of North America Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 60 Rest of North America Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 61 Rest of North America Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 62 Rest of North America Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 63 Key Information – Abbott Laboratories
TABLE 64 Key Information – Sanofi S.A.
TABLE 65 Key Information – Danaher Corporation
TABLE 66 Key Information – Pfizer, Inc.
TABLE 67 KEY INFORMATION - Merck & Co., Inc.
TABLE 68 Key Information – Bristol Myers Squibb Company
TABLE 69 Key Information – Alnylam Pharmaceuticals, Inc.
TABLE 70 Key Information – Emmaus Life Sciences, INC.
TABLE 71 Key Information – Biogen, Inc.
TABLE 72 Key Information – Canthera Discovery Ltd.
List of Figures
FIG 1 Methodology for the research
FIG 2 Swot analysis: Abbott laboratories